COMP <GO>
ARWR vs UNH // RSI-14 & 200D SMA MOMENTUM
Arrowhead Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ARWR 5
— UNH 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: UNH
LAST: $59.57 (-0.55%) • MKT CAP: $8.41B
rsi-technicals
40.2
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
rsi-technicals
55.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARWR VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARWR | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.10% | 12.38% | -1.28 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.8x | 15.3x | +58.53 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 1.84% | 6.25% | -4.41 | UNH | /fcf-yield <GO> |
| Operating Margin | 11.90% | 5.32% | +6.58 | ARWR | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 3.53% | -3.73 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 3.33% | +176.67 | ARWR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 3.09 | +3.51 | ARWR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ARWR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 40.2 | 55.1 | -14.90 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.33 | +0.63 | ARWR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 17.7x | +0.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.41B | $359.43B | -$351.02B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARWR REV | UNH REV | ARWR GROSS % | UNH GROSS % | ARWR FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $829.4M | $447.57B | — | 88.7% | $156.9M | $16.07B |
| FY 2024 | $3.6M | $400.28B | — | 88.3% | -$604.3M | $20.70B |
| FY 2023 | $240.7M | $371.62B | — | 89.6% | -$164.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARWR // BETA 0.96
UNH // BETA 0.33